Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
CytomX Therapeutics, Inc. (CTMX) had Receiveable Turnover of 0.33 for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.66M |
|
$-29.51M |
|
-- |
|
$0.66M |
|
$28.59M |
|
$-27.93M |
|
$1.48M |
|
$-26.45M |
|
$-26.45M |
|
$-26.51M |
|
$-26.51M |
|
$-26.51M |
|
$-26.51M |
|
$-27.93M |
|
$-28.14M |
|
137.94M |
|
137.94M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$143.92M |
|
$1.30M |
|
$7.64M |
|
$151.57M |
|
$46.62M |
|
-- |
|
$5.94M |
|
$52.56M |
|
$99.01M |
|
$97.62M |
|
$99.01M |
|
170.19M |
|
| Cash Flow Statement Financials | |
$-75.59M |
|
$-59.74M |
|
$110.45M |
|
$39.08M |
|
$14.19M |
|
$-24.89M |
|
$6.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-4212.83% |
|
-4212.83% |
|
-- |
|
-3990.21% |
|
-4451.29% |
|
$-75.81M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
|
Receiveable Turnover |
0.33 |
273.26 |
|
-26.78% |
|
-27.16% |
|
-17.49% |
|
-26.78% |
|
$0.58 |
|
$-0.55 |
|
$-0.55 |
|